|
|
Books > Medicine > Pre-clinical medicine: basic sciences > General
This book has resulted a very appreciated help for university
students to successfully pass multiple choice question based
biochemistry exams, which are the most common way of being assessed
in subjects as General Biochemistry, Medical Biochemistry and other
biosciences courses given at many universities throughout the
world. For the student facing such exams, the fact of 'having
understood and memorized' all the contents is not enough. It is
crucial to practice repeatedly the exercise of searching in the
memory for the proper answer, distinguishing it from very similar
options, specifically designed for inducing to error. Facing to
these situations again and again before the exam will reinforce
your memory ability and will surely improve your grade. The 1000
questions are put into 19 content blocks. Within these blocks, to
simulate the exam conditions, I have not made any additional order
(apart from sugar or lipid metabolism, and photosynthesis). Each
block must be addressed after a thorough study of the contents
found in the indicated reference books or the ones given by your
teachers. I have prepared the questions in the same way that I
prepare the exams for my students. They are the fruit of a
methodical and exhaustive review of the indicated bibliography, and
they cover from the most obvious aspects to the trickiest ones,
with the pursuit of 'leaving nothing without being asked'. Surely
the teachers will also find good ideas on 'what and how to ask' for
these blank evenings preparing the proof. Some technical issues: i)
I have chosen a 5-options model (very common in many universities).
You must know that this option entails that a mistake subtracts
0.25 right answers. ii) when a right answer is included in a more
general answer, that is also right, the valid option is the last
one. About me. I got my PhD in Biology at the University of
Barcelona (Spain). I am specialized in macromolecular structure,
molecular simulation, bioinformatics, computational biochemistry,
drug design, ... I combine (when it is possible ) the teaching at a
secondary school with university teaching. I have been assistant
professor of Biochemistry at the University of Barcelona and the
University of Castilla-La Mancha. You can send me at
[email protected] any doubt arisen from the work with the
book, that I will be very glad to answer. I hope it improves your
grade and your learning."
Germination of the thought of "Enzymatic- and Transporter-Based
Drug-Drug Interactions: Progress and Future Challenges" Proceedings
came about as part of the annual meeting of The American
Association of Pharmaceutical Scientists (AAPS) that was held in
San Diego in November of 2007. The attendance of workshop by more
than 250 pharmaceutical scientists reflected the increased interest
in the area of drug-drug interactions (DDIs), the greater focus of
PhRMA, academia, and regulatory agencies, and the rapid pace of
growth in knowledge. One of the aims of the workshop was to address
the progress made in quantitatively predicting enzyme- and
transporter-based DDIs as well as highlighted areas where such
predictions are poor or areas that remain challenging for the
future. Because of the serious clinical implications, initiatives
have arisen from the FDA
(http://www.fda.gov/cber/gdlns/interactstud.htm) to highlight the
importance of enzyme- and transporter-based DDIs. During the past
ten to fifteen years, we have come to realize that transporters, in
addition to enzymes, play a vital role in drug elimination. Such
insight has been possible because of the continued growth in
PK-ADME
(pharmacokinetics-absorption-distribution-metabolism-excretion)
knowledge, fueled by further advances in molecular biology, greater
availability of human tissues, and the development of additional
and sophisticated model systems and sensitive assay methods for
studying drug metabolism and transport in vitro and in vivo. This
has sparked an in-depth probing into mechanisms surrounding DDIs,
resulting from ligand-induced changes in nuclear receptors, as well
as alterations in transporter and enzyme expression and function.
Despite such advances, the in vitro and in vivo study of drug
interactions and the integration of various data sets remain
challenging. Therefore, it has become apparent that a proceeding
that serves to encapsulate current strategies, approaches, methods
and applications is necessary. As Editors, we have assembled a
number of opinion leaders and asked them to contribute chapters
surrounding these issues. Many of these are the original Workshop
speakers whereas others had been selected specially to contribute
on topics related to basic and applied information that had not
been covered in other reference texts on DDI. The resulting tome,
entitled Enzyme- and Transporter-Based Drug Interactions: Progress
and Future Challenges, comprises of four sections. Twenty-eight
chapters covering various topics and perspectives related to the
subject of metabolic and transporter-based drug-drug interactions
are presented.
Recommended use of antioxidant vitamins to treat varied medical
maladies is based on the invalidated free radical theory. The
continued non-acceptance of the null findings of over 500 clinical
trials on vitamin and antioxidant supplements has no scientific
basis or biochemical plausibility. The underlying principles of the
free radical theory have been proven to have repeated
unreliability. It fails to meet the requirements of the scientific
method and lacks reproducibility. Yet, the multi-billion dollar
antioxidant supplement industry continues to thrive and trumpet
false claims for their potentially harmful products. No doubt,
excessive intake of antioxidant vitamins results in increased risk
of heart disease, cancer, strokes and overall mortality. A working
knowledge of redox chemistry is essential to understanding the
hundreds of failed trials testing the efficacy of antioxidant
supplements and antioxidant vitamins. Normal redox homeostasis may
be pathologically disturbed by overzealous use of antioxidants. My
UTOPIA and ROS insufficiency theories present a new perspective
more correctly informed by the most contemporaneous experimental
findings and by the most reliable clinical trials and studies. In
short, electronically modified oxygen derivatives (EMODs) are
essential for human existence and protection. An EMOD insufficiency
"allows" for the development of a multitude of disease entities,
including infections, non-healing wounds, infertility, tumor
development, arteriosclerotic blockages, and cancer growth and
metastasis. There never has been a "war" between EMODs and
antioxidants.
|
|